Back to search

Virginia Tech

Developing Sphingosine-1-Phosphate (Spns2) Inhibitors for the Treatment of Multiple Sclerosis

Abstract

dc:description.abstract

Sphingosine-1-phosphate (S1P) is a ubiquitous signaling molecule. S1P is formed from sphingosine via phosphorylation by one of its two kinases (SphK1 and SphK2). Once produced, it can be exported out of the cell by Spinster homologue 2 (Spns2) or major facilitator domain containing 2B (mfsd2b) where it acts as a ligand for G-protein coupled receptors S1P1-5. S1P has important, ubiquitous extracellular functions in the body including cellular survival, proliferation, and migration. Indeed, lymphocyte trafficking is reliant on the gradient of S1P found where S1P levels are high in blood and low in tissue. This makes the S1P pathway an attractive target for a potential immunosuppressant and anti-inflammatory agent. Disruption of the S1P gradient through genetic knockout and small molecule based Spns2 inhibition have both been shown to provide potential treatment in renal fibrosis. Thus, there is an urgent need for developing Spns2 inhibitors to explore their therapeutic value. Work in this dissertation discloses the design, synthesis, and activities of several highly potent Spns2 inhibitors. Several structures were investigated and allowed for the discovery and development of benzimidazole derivative 4.13h. This structure is comprised of a 3-cyclopropylphenoxy tail, a benzimidazole core, and a piperazine head group. In vitro assays demonstrated the compound has an IC50 = 27 ± 6 nM, making it the most potent Spns2 inhibitor to date. Intraperitoneal (IP) and per oral (PO) administration of 4.13h reduced circulating lymphocyte counts by 49% and 34% respectively, recapitulating the lymphopenia observed with Spns2 knockout mice. Pharmacokinetic studies revealed that 4.13h has a Cmax = 480 nM and a t1/2 = 8.33 h in mice. Taken together, these results suggest that 4.13h presents a novel Spns2 inhibitor that can serve as a chemical tool for exploring Spns2 related biology and as a potential immunosuppressive agent for the treatment of diseases such as multiple sclerosis or renal fibrosis.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Chemistry
Department dc:contributor.department
Chemistry
Grantor dc:publisher
Virginia Tech
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Shrader, Christopher Wayne
Chair dc:contributor.committeechair
  • Santos, Webster
Committee members dc:contributor.committeemember
  • Lowell, Andrew Nesemann
  • Mevers, Emily
  • Matson, John

Subjects

dc:subject × 6

Rights

dc:rights
Statement dc:rights
  • In Copyright
Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Other
vt_gsexam:39500

Chain of custody

source
Harvested from
Virginia Tech
Base URL
vtechworks.lib.vt.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Shrader, Christopher Wayne. Developing Sphingosine-1-Phosphate (Spns2) Inhibitors for the Treatment of Multiple Sclerosis. doctoral thesis, Virginia Tech, 2024. https://hdl.handle.net/10919/118217